Home Amiko Digital Health Limited

Amiko Digital Health Limited

    Amiko Receives CE Mark for Use of the Respiro Platform with Teva’s Spiromax®, Chiesi’s Nexthaler® and GlaxoSmithKline’s Ellipta® Inhalers

    2/5/18: Amiko Digital Health Limited (Amiko), a company that develops advanced medication sensor technologies and AI-powered digital health tools, announced today that the company has received CE Mark for use of the Respiro platform with Teva's Spiromax® inhaler, Chiesi's Nexthaler® inhaler and GlaxoSmithKline's Ellipta® inhaler.

    RECENT COMMENTS